Patents by Inventor Kate MONROE
Kate MONROE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965023Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 9, 2022Date of Patent: April 23, 2024Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
-
Publication number: 20240067723Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: April 10, 2023Publication date: February 29, 2024Applicant: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Patent number: 11667710Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: September 10, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Publication number: 20230107639Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 21, 2022Publication date: April 6, 2023Applicant: Alector LLCInventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
-
Publication number: 20220411503Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 2, 2022Publication date: December 29, 2022Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
-
Publication number: 20220315656Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 9, 2022Publication date: October 6, 2022Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
-
Publication number: 20220281976Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 24, 2022Publication date: September 8, 2022Applicant: Alector LLCInventors: Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
-
Publication number: 20220251190Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 27, 2021Publication date: August 11, 2022Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Francesca AVOGADRI-CONNORS, Seung-Joo LEE, William MONTEITH, Herve RHINN, Arnon ROSENTHAL
-
Patent number: 11390680Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: February 14, 2020Date of Patent: July 19, 2022Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
-
Patent number: 11359014Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 15, 2018Date of Patent: June 14, 2022Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
-
Patent number: 11174313Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 11, 2016Date of Patent: November 16, 2021Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Kate Monroe, Francesca Avogadri-Connors
-
Patent number: 11136390Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 11, 2016Date of Patent: October 5, 2021Assignee: ALECTOR LLCInventors: Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
-
Patent number: 11084875Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: GrantFiled: April 11, 2019Date of Patent: August 10, 2021Assignee: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Publication number: 20210095023Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: September 10, 2020Publication date: April 1, 2021Applicant: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Publication number: 20210017275Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 15, 2018Publication date: January 21, 2021Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
-
Patent number: 10800844Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: October 28, 2016Date of Patent: October 13, 2020Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Publication number: 20200277374Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 14, 2020Publication date: September 3, 2020Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Francesca AVOGADRI-CONNORS, William MONTEITH
-
Patent number: 10590198Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 26, 2016Date of Patent: March 17, 2020Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
-
Publication number: 20190315858Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 11, 2019Publication date: October 17, 2019Applicant: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Publication number: 20190085076Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 11, 2016Publication date: March 21, 2019Applicant: ALECTOR LLCInventors: Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
